Watson and Antares announced the launch of Gelnique (oxybutynin chloride) gel 3% for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency. Gelnique gel 3% is a clear, odorless topical gel available in a metered pump dispenser, offering patients convenient dosing.
Results from a Phase 3 study showed that 84mg of once-daily Gelnique 3% was superior to placebo at relieving OAB symptoms including a reduction in incontinence episodes and urinary frequency, and an increase in urine void volume.
Gelnique gel contains oxybutynin, an antispasmodic, antimuscarinic agent. It is applied once daily to the thigh, abdomen, upper arm or shoulder. Gelnique is already available in a 10% dosage strength that comes in 1g gel packets.
For more information call (888) 435-6478 or visit www.gelnique.com.